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The development and dissemination of antibiotic-resistant bacterial pathogens is a growing
global threat to public health. Novel compounds and/or therapeutic strategies are required to
face the challenge posed, in particular, by Gram-negative bacteria. Here we assess the
combined effect of potent cell-wall synthesis inhibitors with either natural or synthetic
peptides that can act on the outer-membrane. Thus, several linear peptides, either alone or
combined with vancomycin or nisin, were tested against selected Gram-negative pathogens,
and the best one was improved by further engineering. Finally, peptide D-11 and vancomycin
displayed a potent antimicrobial activity at low μM concentrations against a panel of relevant
Gram-negative pathogens. This combination was highly active in biological fluids like blood,
but was non-hemolytic and non-toxic against cell lines. We conclude that vancomycin and D-
11 are safe at >50-fold their MICs. Based on the results obtained, and as a proof of concept for
the newly observed synergy, a Pseudomonas aeruginosa mouse infection model experiment
was also performed, showing a 4 log10 reduction of the pathogen after treatment with the
combination. This approach offers a potent alternative strategy to fight (drug-resistant)
Gram-negative pathogens in humans and mammals.
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Antimicrobial resistance (AMR) is a natural processenhanced by the widespread use and misuse of antibiotics.The critical increase of AMR poses a major and serious
worldwide threat to public health. Following the introduction of
lipopeptides in 2003, hardly any new families of antibiotics have
been developed, while the existing drugs are rapidly becoming
ineffective1–4. Currently, 700,000 deaths per year can be attrib-
uted to the spread of antimicrobial resistance and this number is
estimated to increase to 10,000,000 by the year 20505. In 2017, the
World Health Organization (WHO) published the global priority
list, with 12 antibiotic-resistant bacteria for which new anti-
microbials or therapeutic strategies are urgently needed6.
Remarkably, 9 of the 12 “superbugs” listed are Gram-negative
pathogens. Their outer-membrane acts as an efficient barrier to
prevent various antimicrobials from reaching their targets at the
inner membrane and/or the cytoplasm, which complicates the
development of efficient treatments against (multidrug-resistant,
MDR) bacteria7,8. Passage of the outer-membrane is an essential
step in the killing of Gram-negative cells by many antibiotics and
antimicrobials. The efficacy of individual antimicrobials can be
enhanced by combination with other (either antimicrobial or
inactive) permeabilizing compounds9,10.
Cell-wall biosynthesis and maintenance are essential processes
in bacteria and their inhibition leads to growth arrestment and
death. In fact, diverse groups of successful antibiotics abolish cell-
wall biosynthesis as their primary mechanism of action. Lipid II is
a key and highly conserved molecule bringing the cell-wall
building blocks to the outside of the cellular membrane11. Nisin
and vancomycin are potent antimicrobials inhibiting cell-wall
biosynthesis by binding to lipid II at the cell membrane using two
different binding motifs. They have low micromolar minimal
inhibitory concentrations (MICs) but are poorly active on
Gram-negative bacteria due to the presence of their outer-
membrane12–14. Recently, the replacement of the C terminus of
the lantibiotic nisin with short peptide sequences increased the
antimicrobial activity 4- to 12-fold against relevant Gram-negative
microorganisms15, showing the outer-membrane permeating
potency of these peptides. Thus, we hypothesized that if we could
find compounds that can perturb or transiently permeate the
Gram-negative outer-membrane, this would enable vancomycin
or nisin to access the periplasm and reach lipid II, resulting in
substantial activity against Gram-negative pathogens16.
In this study, eight, either natural or synthetic, peptides ranging
in size between 11 and 23 amino acids, which exert low to modest
activity against Gram-negative bacteria, were selected from lit-
erature to work as possible Gram-negative outer-membrane-
penetrating or -perturbing peptides, thereby exposing lipid II in
the inner membrane to either nisin or vancomycin. A first
screening was done using nisin or vancomycin as a partner in
combination with either peptide. Nine additional variants of the
best peptide identified, i.e., L-8, were designed and the best
candidate was used to potentiate the activity of the anti-Gram-
positive antibiotic vancomycin. Eventually, the D-11 peptide was
obtained, which showed very high synergistic activity when
combined with vancomycin. We demonstrate its safety with
respect to cytotoxicity, hemolysis, and activity in vivo, indicating
its high potential in combination with vancomycin as a future
therapeutic agent.
Results
Minimal inhibitory concentration (MICs) of peptides alone
and in combination with lipid II-targeting antimicrobials.
Vancomycin and nisin were selected because they are potent
antimicrobials against Gram-positive bacteria whereas they dis-
play low or absent activity against Gram-negative bacteria. Also,
they are considered as safe antimicrobials in food preservation
(nisin)17 or in clinical application (vancomycin)14, and both use
the same target, lipid II, to kill bacteria. Eight peptides were
selected from literature that displayed low or modest activity
against Gram-negative bacteria. Initially, activity tests for van-
comycin, nisin and the selected peptides were performed against
five clinically relevant Gram-negative pathogens (Table 1). Their
MICs ranged from 0.5 µM to more than 256 µM in a strain-
dependent manner and, as expected, the antimicrobial activity of
either vancomycin or nisin was quite low (Table 1).
After this test, the peptides L-1 to L-8 were combined with
either vancomycin or nisin and initially tested against E. coli
Table 1 Sequences and MIC (µM) of the different peptides and antimicrobials used in this work. D amino acids are indicated in
lowercase.











L-1 GNNRPVYIPQPRPPHPRL 62 0.5 5 >64 >64 8
L-2 VDKPPYLPRPRPPRRIYNR 63 4 8 >64 16 >64
L-3 VDKGSYLPRPTPPRPIYNRN-NH2 64 3 16 32 8 >32
L-4 RLLFRKIRRLKR 65 64 >256 >128 >128 >256
L-5 RIWVIWRR-NH2 66 3 6 3 2 5
L-6 RRLFRRILRWL-NH2 67 2 4 3 2 8
L-7 GIGKHVGKALKGLKGLLKGLGEC 68 6 12 13 2 8
L-8 KRIVQRIKKWLR-NH2 69 4 64 16 16 32
L-9 -RIVQRIKKW-R-NH2 This work 256 >256 >256 >256 >256
L-10 -RIVQRIKKWL--NH2 This work 32 64 16 128 >256
L-11 -RIVQRIKKWLR-NH2 This work 12 32 16 >64 128
L-12 -KIVQRIKKWLR-NH2 This work 16 32 16 128 256
L-13 -AIVQRIKKWLR-NH2 This work 12 24 16 128 128
L-14 -RIRKRIKKWLR-NH2 This work 16 >256 16 >256 >256
L-15 -RIKRRIKKWLR-NH2 This work 24 >256 32 >256 >256
D-11 rivqrikkwlr-NH2 This work 4 32 16 8 32
D-11R rlwkkirqvir-NH2 This work 8 32 16 64 32
Vancomycin 64 128 128 32 192
Nisin 12 48 36 6 32
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LMG 15862. Interestingly, all the peptides tested displayed
some synergistic effect with nisin against E. coli, with the
exception of L-2 and L-3 that only showed an additive effect
(Table 2). However, in the combination with vancomycin, the
effect was mainly additive and L-8, with a Fractional Inhibitory
Concentration Index (FICI) of 0.563, showed the best synergy
(Table 2). Considering the best reduction in the MIC of either
vancomycin or nisin, the peptides L-1, L-5, L-6, L-7 and L-8
were selected for further characterization of the synergistic
effect against a panel of 4 other Gram-negative medically
relevant bacteria (Table 2).
The combination of the selected peptides with nisin was
synergistic in all the cases against all the bacteria tested with the
exception of the L-1 peptide (Table 2). The combination of L-8
with either vancomycin or nisin displayed the best synergism
against almost all of the five Gram-negative pathogens, while the
combined effect of the other peptides with vancomycin was
modest and, in general, additive, and strain-specific (Table 2).
The peptide L-6, which was also (less) synergistic in some
combinations, was discarded because it showed rather high
hemolytic activity in the previous studies18. Notably, L-8 had very
low hemolytic activity19, which made it the best candidate for
further studies. Based on these results, peptide L-8 was selected
for a round of further modifications.
L-8 peptide improvement. In order to increase the combined
effect, seven variants of L-8 were designed. Several parameters
such as peptide truncation, role of arginine/lysine, amphiphilicity,
and hydrophobicity were explored20. Based on this, three shorter
variants were designed to increase the drug potential of the
peptide and then, for the best one, another four variants were
designed (Table 1 and Supplementary Fig. 1). In general, none of
the newly designed peptides systematically outperformed L-8
(Table 1). However, in combination with either vancomycin or
nisin an astonishing improvement of the synergy was observed
for the peptide L-11 (Table 3). This peptide, being just one amino
acid smaller than the original L-8, was better in synergy with
vancomycin in all the cases against all the bacteria as well as in
the combination with nisin, with the exception of Pseudomonas,
where the FICI value was the same (Table 3). The reduction in the
MIC of vancomycin in combination with L-11 ranged between 8-
fold reduction for Pseudomonas and 32-fold for Klebsiella. The
synergistic effect varied in a strain-specific manner with the other
designed peptides (Table 3). Considering several parameters as
Table 2 Combined activity of L-1 to L-8 peptides and either vancomycin or nisin against five Gram-negative pathogens.
L-1 L-2 L-3 L-4 L-5 L-6 L-7 L-8
E. coli LMG 15862
Vancomycin 32 32 32 16 32 16 16 32
Peptide 0.125 2 1.5 16 0.75 1 3 0.25
FICI 0.75 1 1 0.75 0.75 0.75 0.75 0.563
Nisin 1.5 1.5 3 3 0.75 1.5 1.5 1.5
Peptide 0.13 2 1.5 8 0.75 0.5 1.5 1
FICI 0.375 0.625 0.75 0.375 0.313 0.375 0.375 0.375
L-1 L-5 L-6 L-7 L-8
P. aeruginosa LMG 6395
Vancomycin 128 128 32 128 64
Peptide 32 1.5 1.5 6.5 8
FICI 1.25 1.5 0.75 1.5 1
Nisin 4.5 2.25 4.5 4.5 4.5
Peptide 64 0.75 0.75 3.25 1
FICI 0.625 0.313 0.375 0.375 0.188
K. pneumoniae LMG 20218
Vancomycin 64 64 32 64 8
Peptide 0.625 3 1 3 8
FICI 0.625 1 0.5 0.75 0.188
Nisin 6 6 3 3 0.75
Peptide 1.25 1.5 0.5 0.75 4
FICI 0.375 0.375 0.188 0.125 0.078
A. baumannii LMG 01041
Vancomycin 16 16 8 16 4
Peptide 16 0.5 0.5 0.25 4
FICI 0.625 0.75 0.5 0.625 0.375
Nisin 1.5 0.75 0.75 0.75 0.19
Peptide 64 0.5 0.5 0.5 1
FICI 0.546 0.375 0.375 0.375 0.094
E. aerogenes LMG 02094
Vancomycin 192 192 64 192 48
Peptide 8 5 2 4 4
FICI 2 2 0.583 1.5 0.375
Nisin 4 4 2 4 2
Peptide 4 1.25 1 1 8
FICI 0.625 0.375 0.188 0.25 0.313
In the table are listed the MICs (µM) for vancomycin, nisin and the peptides for the best combination, as well as the FICI calculation. For an explanation of FICI and how it is calculated see the “Methods”
section. Synergistic combinations are labeled in bold. For the FICI calculations twice the highest concentration tested was used in the cases where the MIC was not reached. Individual MICs are listed in
Table 1.
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size, activity alone and activity in the combinations, peptide L-11
was selected for further (pre-clinical) characterization.
Plasma stability. In view of the clinical potential, plasma stability
is a desirable quality of newly designed antimicrobials21,22. So,
before further analysis, the stability of L-11 in plasma was ana-
lyzed. The peptide was incubated in PBS (Fig. 1a) and plasma
(Fig. 1b), and the reduction in the antimicrobial activity was
tested by a spot-on-lawn assay against K. pneumoniae. The
peptide L-11 was not very stable in plasma, being almost com-
pletely degraded within the first 3 h (Fig. 1b). In order to increase
the stability, the peptide was synthesized with only D-amino acids
(D-11) making it resistant against peptidases and proteases23.
Moreover, reversed peptides (with a reversal of the peptide
sequence) have been reported to be interesting in peptidomi-
metics and can display good activity18,24. Thus, both variants
were synthesized and assayed (D-11 and D-11R). As we can see in
Fig. 1b, both D-11, as well as its reversed peptide D-11R, were
completely resistant to degradation in plasma.
Antimicrobial activity and synergy of the newly designed
peptides. The introduction of D-amino acids or the change in the
order of the amino acids may abolish a (putative) receptor
interaction, thus allowing to establish whether or not a specific
Table 3 Combined activity of L-peptides and either vancomycin or nisin against five Gram-negative pathogens.
L-8 L-9 L-10 L-11 L-12 L-13 L-14 L-15
E. coli LMG 15862
Vancomycin 32 8 8 4 4 4 4 4
Peptide 0.25 16 4 1.5 2 3 2 3
FICI 0.563 0.188 0.25 0.188 0.188 0.313 0.188 0.188
Nisin 1.5 6 3 1.5 1.5 1.5 3 3
Peptide 1 64 2 1.5 2 1.5 2 3
FICI 0.375 0.75 0.313 0.25 0.25 0.25 0.375 0.375
P. aeruginosa LMG 6395
Vancomycin 64 ND 16 16 16 4 4 16
Peptide 8 ND 2 2 2 8 8 8
FICI 1 ND 0.25 0.25 0.25 0.531 0.531 0.5
Nisin 4.5 ND 4.5 4.5 4.5 4.5 2.25 9
Peptide 1 ND 4 1 4 8 4 8
FICI 0.188 ND 0.375 0.188 0.375 0.625 0.313 0.5
K. pneumoniae LMG 20218
Vancomycin 8 ND 16 4 16 16 ND ND
Peptide 8 ND 16 2 8 3 ND ND
FICI 0.188 ND 0.375 0.094 0.375 0.25 ND ND
Nisin 0.75 ND 3 0.75 0.75 1.5 ND ND
Peptide 4 ND 1 1 2 3 ND ND
FICI 0.078 ND 0.078 0.047 0.078 0.156 ND ND
A. baumannii LMG 01041
Vancomycin 4 ND 1 2 4 4 ND ND
Peptide 4 ND 16 1 4 8 ND ND
FICI 0.375 ND 0.125 0.070 0.156 0.188 ND ND
Nisin 0.19 ND 0.375 0.19 0.375 0.375 ND ND
Peptide 1 ND 16 4 16 32 ND ND
FICI 0.094 ND 0.188 0.070 0.188 0.313 ND ND
E. aerogenes LMG 02094
Vancomycin 48 ND ND 12 12 12 ND ND
Peptide 4 ND ND 8 16 16 ND ND
FICI 0.375 ND ND 0.125 0.125 0.188 ND ND
Nisin 2 ND ND 4 4 4 ND ND
Peptide 8 ND ND 8 1 8 ND ND
FICI 0.313 ND ND 0.188 0.128 0.188 ND ND
In this table, the MICs (µM) of vancomycin, nisin, and the peptides for the best combination, as well as the FICI calculation, are listed. Peptides with a better synergism coefficient than L-8 are displayed in
bold. For the FICI calculations, twice the highest concentration tested was used in the cases where the MIC was not reached. Individual MICs are listed in Table 1.
ND no synergy determined.
PBS         L-11          D-11        D-11R 
PBS










Fig. 1 Plasma stability for the peptides L-11, D-11 and D-11R. a Antimicrobial activity of the peptides L-11, D-11, and D-11R against K. pneumoniae
LMG 20218 after their incubation in PBS. b Antimicrobial activity of the peptides L-11, D-11, and D-11R after their incubation in human plasma.
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(proteinaceous) receptor is playing a role. For this reason, and to
determine whether the changes affected the previously observed
activity, the new variants were tested alone and in synergy with
vancomycin against pathogenic multiresistant bacteria, including
clinical isolates (Table 1). The impact of D-amino acid replace-
ment in L-11 entailed a drastic improvement against E. aerogenes
and A. baumannii (4 and >8-fold MIC reduction, respectively, for
the peptide alone), although no important changes against the
rest of the panel was observed. The reversed D-peptide was in
general either equally or 2- to 8-fold less active than the D-peptide
against the whole panel (Table 1). D-11 and D-11R showed, just
as L-11, a strong synergistic effect in all the combinations with
either vancomycin or nisin (Supplementary Table 1). Never-
theless, the combinations of D-11 and either vancomycin or nisin
showed slightly less synergism than the L-11 peptide with a FICI
value ranging between 0.078 and 0.25 but a similar reduction in
the MIC value for vancomycin or nisin, so these values still
indicate a very strong in vitro synergy (Supplementary Table 1).
In general, the combination with nisin was more effective and
yielded the lowest FICI values. Notably, the D-peptides exhibited
an enhanced activity against Gram-negative pathogens, when
compared to the L-counterpart. The reversed peptide sequence
did not largely change the activities of the peptides except against
A. baumannii. These results suggest that the selected L-11, D-11,
and D-11R do not interact with a specific proteinaceous receptor,
which would require stereospecific interactions.
Since D-amino acids confer higher resistance against proteo-
lysis, are more stable in serum and blood, and because the activity
in synergy was not greatly altered, D-11 was selected for further
tests in combination with vancomycin against clinical isolated
MDR bacteria. Synergy with vancomycin may constitute an
interesting therapeutic alternative, since it is smaller than nisin
and -in contrast to nisin- is currently used as an antibiotic in
clinical therapy. As before (Table 1), the vancomycin activity
alone against these strains was low, while the combined activity of
vancomycin and D-11 was strain-specific and synergistic
(Table 4). The most sensitive strains to vancomycin in
combination with D-11 were E. coli and A. baumannii, and the
best synergistic effect was obtained for the strains E. coli ATCC
BAA-2452, K. pneumoniae ATCC BAA-2524, K. pneumoniae
B1945, and A. baumannii ATCC BAA-1605 (Table 4).
The bactericidal effect of vancomycin, D-11, and the
combinations thereof were determined against five Gram-
negative strains. The final concentration of the compounds used
was 10-fold the MIC of each compound measured either
individually (Table 1) or in combination (Table 3). Unlike the
positive controls (untreated cells), no colonies of any of the five
Gram-negative pathogens could grow after treatment incubation
for 3 h (Supplementary Fig. 2). There was no growth recovery
after exposure to vancomycin, D-11, and the combinations
thereof, so both the compounds alone and the combinations
thereof are bactericidal.
Mechanistic aspects of the synergistic action. According to our
hypothesis, the peptide is perturbing the outer-membrane,
enabling vancomycin to access the periplasm, thus reaching its
target lipid II. To test whether the outer-membrane is the main
target of D-11, the antimicrobial activity of D-11 and vancomycin
was tested against 5 different Gram-positive bacteria, which do
not have an outer-membrane (Supplementary Table 2). D-11
MIC was above 64 µM in all cases (with the exception of E.
faecium that was 10.4 µM). In addition, no synergy in the com-
bination with vancomycin was observed. This data suggests that
the activity of D-11 is due to its action on the outer-membrane.
The role of LPS and Mg2+ in the activity. To prove the role of the
outer-membrane structure in the synergistic killing mechanism,
we tested the influence of LPS and magnesium ions on the activity
of vancomycin and D-11 against the Gram-negative bacteria
panel. Both vancomycin and D-11 (especially this one) exhibited
a reduced antimicrobial effect against all the tested pathogens
when the cells were grown in the presence of exogenous LPS or
Mg2+ (Supplementary Table 3). When LPS was in the medium,
the MICs of vancomycin against Gram-negative pathogens
increased 2-fold, except against A. baumannii. Remarkably, 2- to
more than 16-fold D-11 was needed to inhibit the growth of
Gram-negative pathogens in the presence of LPS and this
reduction was even more drastic in the presence of an outer-
membrane-stabilizing agent as Mg2+ (Supplementary Table 3).
The effect of exogenous LPS and Mg2+ was also analyzed in the
synergistic combination. As depicted in Fig. 2a, LPS considerably
suppressed the ability of D-11 to potentiate vancomycin against
Gram-negative pathogens. As an example, 2 µM vancomycin and
1 µM D-11 can inhibit the growth of K. pneumoniae without the
addition of LPS. However, at least 32 µM vancomycin and 16 µM
D-11 were needed after the addition of excess LPS. When 21 mM
Mg2+ was added to the growth medium for the checkerboard
Table 4 Combined activity of D-11 and vancomycin (µM) against an extended panel of MDR Gram-negative clinical isolated
pathogens.
Strains MICA MICB MICAB MICAC FICI
E. coli ATCC 25922 >88.32 5.36 5.52 1.6 0.329
E. coli ATCC BAA-2452 >88.32 5.36 2.76 0.80 0.164
E. coli B1927 88.32 2.68 5.52 1.6 0.659
K. pneumoniae ATCC700603 >88.32 >85.68 11.04 10.71 0.081
K. pneumoniae ATCC BAA-2524 >88.32 >85.68 11.04 3.21 0.081
K. pneumoniae B1945 >88.32 21.41 11.04 3.21 0.212
P. aeruginosa ATCC 27853 >88.32 42.84 11.04 10.71 0.312
P. aeruginosa ATCC BAA-2108 >88.32 >85.68 44.15 42.84 0.499
P. aeruginosa B1954 88.32 85.68 44.15 42.84 1
P. aeruginosa PA14 88.32 128 32 8 0.422
A. baumannii ATCC 17978 88.32 10.71 5.52 1.61 0.22
A. baumannii ATCC BAA-1605 44.16 10.71 2.76 0.80 0.137
A. baumannii B2026 22.08 10.71 2.76 2.68 0.376
MICA is the MIC of vancomycin alone; MICB corresponds to the MIC of D-11 when used alone; MICAB is the MIC of vancomycin in combination with the peptide at the MICAC concentration. MICAC is the
MIC of D-11 when used with the MICAB concentration of vancomycin. Synergistic combinations are labeled in bold. For the FICI calculations, twice the highest concentration tested was used in the cases
where the MIC was not reached.
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broth microdilution assays, D-11 was not able to potentiate
vancomycin against any of the five Gram-negative pathogens,
which grew at the tested concentrations (Fig. 2a). This is
consistent with the results when vancomycin and D-11 were
tested alone in the presence of LPS and Mg2+ (Supplementary
Table 3) and suggests that the outer-membrane is the main target
for D-11.
D-11 is perturbing the outer-membrane. The activity of D-11 on
the outer-membrane was tested measuring NPN (1-N-phe-
nylnaphthylamine) uptake. The outer-membrane was permeabi-
lized by D-11 in a dose-depending-manner in all the Gram-
negative bacteria tested (Fig. 2b). As expected, no permeabiliza-
tion was observed for vancomycin, while polymyxin B (positive
control) exerted a strong activity. These results suggest that the
D-11 peptide can disrupt the integrity of the outer-membrane of
these Gram-negative pathogens via association with LPS, thereby
enhancing the permeability of the outer-membrane. This helps to
sensitize the Gram-negative pathogens to antibiotics as vanco-
mycin that, otherwise, are restricted to act against Gram-positive
bacteria.
Cell toxicity and hemolytic activity of vancomycin and D-11. In
order to prove the safety of vancomycin, D-11, and their
combinations, toxicity tests against human cell lines and hRBCs
were performed. As we can see in Fig. 3a, vancomycin and D-11
did not affect the viability of human HEK-293 cells, neither alone
nor in combination at all the concentrations tested (up to 88 µM).
After that, fresh hRBCs were used for the hemolytic tests. Van-
comycin and D-11 did not cause any hemolysis of hRBCs even at
concentrations as high as 500 and 600 µM, respectively (Supple-
mentary Table 4).
When combined, vancomycin and D-11 did not cause
hemolysis at the highest concentration tested. The cell selectivity
of the peptides is identified as the therapeutic index (TI)19,25,
which is a parameter related to the toxicity and the effect of drugs
(Supplementary Table 4). A higher TI is preferable for an
antimicrobial to be considered safe. The TI of vancomycin and D-
11 was 11.4 and 39.03, respectively. The TI of D-11 is ~3.4-fold
higher than that of vancomycin and this highlights the safety of
peptide D-11.
Antimicrobial activity in blood. The stability of D-11 was pre-
viously confirmed in plasma. However, whole blood is a complex
medium in which the synergistic interaction between vancomycin
and D-11 can be affected by many additional parameters and
factors. An in vitro bacteremia infection model was developed by
the infection of whole blood with 108 colony forming units
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Fig. 2 Effect of LPS in the D-11/vancomycin synergism and outer-membrane permeabilization assay. a Checkerboard broth microdilution assay diagram
showing the effect of LPS and Mg2+ in the D-11/vancomycin synergistic relation. Dark region represents higher cell density. b Dose-dependent outer-
membrane permeabilization by D-11 against different Gram-negative bacteria. Polymyxin B was used as a positive control and vancomycin as negative.
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(CFU)/mL of K. pneumoniae LMG 20218. 10 µL of each one of
the tubes were collected at different times, they were decimal
serially diluted and plated to quantify the evolution of the
infection in blood. As we can see in Fig. 3b, in the presence of
vancomycin and D-11, the number of colonies observed was
always lower than that of the controls (vancomycin alone or D-11
alone) and during the different time points, with the exception of
the combination of 2 µM vancomycin and 4 µM D-11. After 6 h
of incubation, 1012 CFU/mL were counted for the negative con-
trols as well as for the treatment with 8, 4, and 2 µM vancomycin
(1010 CFU/mL for the treatment with 16 µM vancomycin). In the
D-11 treated blood, 1012 CFU/mL were counted for the negative
control (just D-11), 1010 CFU/mL for the combination with 2 µM
vancomycin, 106 CFU/mL for the combination with 4 and 8 µM
vancomycin and 104 CFU/mL for the combination with 16 µM
vancomycin.
A proof of concept. The in vivo efficacy. Encouraged by the
in vitro results and the potential of dose-sparing drug combi-
nations in therapy, we tested the efficacy of D-11 in combination
with vancomycin in a murine abscess model of P. aeruginosa
PA14 (Fig. 3c). Here, we observed that the combination of D-11
(10 mg/kg) and vancomycin (3 mg/kg) was highly efficacious,
causing a more than 4 log 10 reduction of CFU in the abscess
(Fig. 3c), whereas after treatment with the individual com-
pounds the cell count was similar to that of the saline negative
control.
Discussion
Combined antibiotic therapy has been pivotal in the treatment of
bacterial infections such as tuberculosis and can prevent resis-
tance appearance26,27. In addition, (antimicrobial) peptides con-
stitute a yet unused alternative in antimicrobial therapy in spite of
their potential5. Here, we attempted to expand the spectrum of
lipid II binding antimicrobials such as vancomycin and nisin, so
that they can be used against (resistant) Gram-negative bacteria
by a synergy strategy using natural or synthetic peptides.
Compounds with different targets on bacterial cells can display
very good synergistic effects against pathogens, thereby allowing
dose-sparing and reducing their individual toxicity, which has an
enormous potential in therapy10,28,29. In this work, several pep-
tides from different origins were selected and tested for synergy
together with two classes of lipid II binding antimicrobials
(vancomycin and nisin). Additionally, engineering of the best hits
provided a variant, L-11, with great potential to extend vanco-
mycin’s spectrum against (MDR) Gram-negative pathogens.
Synergies of vancomycin with other antimicrobials are well
documented when targeting Gram-positive bacteria30–32, as well
as its synergy in combination with outer-membrane perturbing
(or not33) antibiotics as colistins34,35. However, these combina-
tions are still under study because of the relatively high toxicity
observed36. There is not much information available on the
synergy of vancomycin and peptides against Gram-negative
bacteria and, if there are data, the observed effect is additive and
the concentrations of vancomycin needed in these combinations
are outside of the clinically relevant range9,37,38.


























































































































Fig. 3 Toxicity and activity ex vivo/in vivo of D-11 with or without vancomycin. a Effect on the cell viability for vancomycin (vanco.), D-11, and their
combination against HEK-293 cells. b Ex vivo bacteremia model for vancomycin, D-11, and their combinations. 10 µL of serial decimal dilutions of each one
of the combinations of vancomycin (16, 8, 4, and 2 µM) with/without D-11 (4 µM) tested in blood were dropped. c In vivo efficacy of vancomycin and D-11
alone and its combination (comb.) against P. aeruginosa PA14. Saline is the negative control.
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Plasma stability is a key factor during the clinical development
of a compound and peptides that have a short half-life are unlike
to reach clinical application21,22,39. It is known that D-amino
acids are protected against the action of peptidases23,40, thus, two
total D-amino acids forms were synthesized: the direct one (D-11)
and the reversed one (D-11R). These two variants were com-
pletely stable in plasma and largely retain the activity against an
(MDR) Gram-negative bacteria panel. The fact that both the D-
and L-amino acids-containing peptides were similarly active
indicates that the activity does not rely on binding to a specific
receptor and therefore its ability to interact with the outer-
membrane was tested.
The most variable part in the outer-membrane is the LPS. To
date, more than 200 different LPS forms have been described just
for E. coli (ECODAB database)41. LPS is a polyanionic molecule
with numerous phosphate groups that generates repulsive forces
(due to accumulation of the negative charges) that are screened
and bridged by the divalent cations (Mg2+ and Ca2+) which are
known to be crucial for the integrity of the outer-membrane42.
Our data suggest that this peptide is prone to interact with LPS,
causing outer-membrane perturbation, which potentiates the
activity of Gram-positive-specific antimicrobials (e.g., vancomy-
cin and nisin) against Gram-negative pathogens, including
antibiotic-resistant strains. The presence of Mg2+ could influence
the MIC, not only because of an increased outer-membrane
stability, but also because of its electrostatic competition with D-
11 (pI= 12.3). In fact, in the presence of Mg2+, a larger peptide
concentration is needed to reach a coverage high enough on the
membrane surface to permeabilize it43. Additionally, NPN per-
meabilization in the presence of D-11 indicates that the outer-
membrane is altered, in a similar way as polymyxin B does. This
kind of activity has been previously reported for small α-helical
and/or cationic peptides44–46. Alteration of the overall structure
of the outer-membrane is, in principle, difficult to achieve
through simple point mutations but would require a deep change
in the Gram-negative bacterial physiology. Thus, a compound
acting on this essential component constitutes an important
advance in anti-Gram-negative antibiotic therapy.
Another important point addressed in this study is the absence
of toxicity against HEK-293 cells and also the absence of hemo-
lytic activity even at high concentrations. This is especially
important since D-11 is a cationic peptide, which are usually not
toxic against cells lines but they are often hemolytic and poorly
stable in plasma47.
Finally, the combination was tested in a bacteremia model in
blood. The activity of exogenous antimicrobial peptides in blood
has been referred previously against both Gram-negative and
positive bacteria48,49, but never in synergy tests. The combination
of D-11 and vancomycin was highly active in blood, controlling
the infection by K. pneumoniae in the conditions tested. Impor-
tantly, the concentration of vancomycin used in this study falls
within the dose range of vancomycin currently applied in humans
in the case of Gram-positive bacterial infections (MDR organisms
may require daily doses up to 60 mg/kg, equivalent to ~40 µM,
www.drugs.com). The in vitro experiments suggest that (combi-
nations of) vancomycin and D-11 are safe at therapeutic con-
centrations and that the antimicrobial activity of the synergy
takes place efficiently in human fluids like blood. These data
encouraged us for an in vivo experiment, since the application of
antimicrobial peptides often fails due to their low activity in the
presence of plasma50. As a proof of concept, mice were infected
with P. aeruginosa, and after the treatments, we observed an
important reduction in the CFU in the mice treated with the
combination, whereas the single components did not show this
effect. Similar results have been observed for the combination of
the antiparasitic drug pentamidine (inactive against bacteria) with
some antibiotics51. Pentamidine behaves as a powerful adjuvant
sensitizing Gram-negative bacteria to typical anti-Gram-positive
antibiotics or even to polymyxins in resistant organisms.
Remarkably, the poor combined effect with vancomycin suggests
a different mechanism of action that could be even com-
plementary in the treatment of Gram-negative pathogens51.
In summary, the combinations here described constitute a
therapeutic approach to deal with (MDR) Gram-negative
pathogens. The efficacy of vancomycin and D-11 further indi-
cates their high potential for clinical use. In spite of the relatively
low activity of D-11 alone, the astonishing synergism of D-11
with vancomycin and nisin raises the possibility of D-11 to be
registered as an adjuvant instead of an antimicrobial itself. The D-
11 peptide fulfills the requirement to be considered as a good
drug candidate: high efficacy (in synergy), low toxicity to
eukaryotic cells, blood stability, high proteolytic stability, and low
cost20. So far all the results indicate that D-11 has the potential to
become an important drug to combat the emerging resistance
problem that the world is facing52. Further development is cur-
rently ongoing to collect all the pre-clinical data to enable first in
human studies.
Methods
Bacterial strains, cell lines, and growth conditions. The bacterial strains used in
this study are listed in Supplementary Table 5. Gram-negative bacteria were rou-
tinely grown in LB medium (Formedium, Norfolk, UK) and shaking (200 rpm) at
37 °C, while Gram-positive strains were grown staticly in M-17 broth (BD Difco,
New Jersey, US) plus 0.5% glucose (GM-17) at 37 °C with the exception of
Streptococcus strains that were cultured in C+ Y medium as described by Aprianto
et al.53. For solid media agar at 1.5 % final concentration was added.
The human embryonic kidney cell line HEK-293 was obtained from the
American type culture collection (ATCC) and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) growth medium supplemented with 1% non-essential
amino acids (NEAA) and 10% fetal bovine serum (FBS) (Sigma-Aldrich, Ontario,
Canada).
Peptides, antimicrobials, reagents, and chemicals. The peptides used in this
work were synthesized by Pepscan (Lelystad, The Netherland) (Table 1). For the
purification and quantification of nisin, commercial nisin was suspended in 0.05%
acetic acid and further purified by HPLC (Agilent 1260 Infinity LC) equipped with
a semi-preparative C12 column (Phenomenex 250 × 10mm). The fractions were
collected, tested for activity against L. lactis, and analyzed with MALDI-TOF. The
active, fully dehydrated and pure fractions were freeze-dried. The freeze-dried nisin
was weighted and dissolved with 0.05% acetic acid54. Vancomycin, polymyxin B,
MgCl2, lipopolysaccharide (LPS) from Escherichia coli O55:B5, HEPES buffer, and
chloral hydrate were purchased from Sigma-Aldrich. Sodium phosphate tablets,
DMEM, non-essential amino acids (NEAA) were purchased from ThermoFisher
Scientific (Waltham, Massachusetts, USA). CellTiter-glo reagent was purchased
from Promega (Leiden, the Netherlands). Human plasma EDTA K2 Mixed-Gender
was purchased from Sera Laboratories International, Ltd (West Sussex, United
Kingdom).
MIC determination and synergy test. MIC tests were performed in triplicate by
liquid growth inhibition microdilution assays in sterile polypropylene microtiter
plates according to the Clinical and Laboratory Standards Institute (CLSI) guide-
line for bacteria that grow aerobically55. Briefly, the indicator strains were first
streaked on the appropriate agar plate, and then single colonies were picked and
incubated overnight in liquid broth. The final inoculum of bacteria was 5*105
CFU/mL prepared in CAMHB (cationic adjusted Mueller–Hinton broth, Sigma-
Aldrich) or CAMHB plus 5% of lysed horse blood (TCS Biosciences, Buckingham,
UK) in the case of S. pneumoniae. The antimicrobials were 2-fold serially diluted
and 50 µL diluted bacterial suspension was added to each well to make the final
volume 100 µL. The microtiter plates and the count plates were incubated at 37 °C
for 16–20 h without shaking. Growth inhibition was assessed by measuring the
OD600 using a microplate reader (Tecan Infinity F200). The lowest concentration of
the antimicrobials that inhibits visible growth of the indicator strain is identified as
the MIC value.
For the synergy test, standard checkerboard broth microdilution assays were
conducted to test the synergistic effect of combined antimicrobials using the same
condition as before51,56. Vancomycin or nisin (compound A) was loaded 2-fold
serially diluted at the X axis, while peptides (compound B) were 2-fold serially
diluted at the Y axis. The initial concentration of both peptides was their individual
MIC. 50 µL fresh bacterial suspension prepared as above was added to the wells
already containing the antimicrobial compound mixture to achieve 100 µL final
volume per well.
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The fractional inhibitory concentration (FIC) indices57 were calculated using
the formula FICI= FICa+ FICb=MICac/MICa+MICbc/MICb, to determine
whether the combination is additive, synergistic or antagonistic51,57. The MICa and
MICb is the MIC of compound A or B alone, respectively. MICac is the MIC of
compound A in combination with compound B and MICbc is the MIC of
compound B when it was combined with compound A. The FIC corresponds to the
MIC of a compound in combination with the other compound, divided by the MIC
of the compound alone. FICa is FIC of compound A while FICb is FIC of
compound B. The FICI was interpreted according to EUCAST58 as follows:
synergistic, FICI ≤ 0.5; additive,0.5 < FICI ≤ 1; indifferent, 1 < FICI < 2;
antagonistic, FICI ≥ 2.
For the bactericidal effect testing, the bacteria were inoculated in CAMHB
medium at 5 × 105 CFU/mL and incubated at 37 °C for 3 h in the presence of
vancomycin, D-11 alone or their combinations at 10× MIC concentrations (Tables 1
and 3). After that, 50 µL of a 103-fold diluted sample were plated on LB agar59.
Plasma stability test. For plasma stability, the peptides were lyophilized and
resuspended in plasma or PBS (as a control) at a final concentration of 3.2 mM.
After that, the peptides were incubated with shaking (200 rpm) during 6 h at 37 °C.
At time 1, 3, and 6 h, 10 µL samples were tested against K. pneumoniae LMG 20218
by a spot-on-lawn test. Reduction in the size of the halo was related to the
degradation of the peptide. The test was performed in triplicate.
Mechanism of action of selected peptides
Effect of LPS and Mg2+ on the activity and synergy of selected peptides. The effect of
LPS (the major component of the outer-membrane) and Mg2+ (divalent cations
are involved in an increase of the stability of the outer-membrane and they are
essential for its integrity) on the activity of peptide D-11 alone and/or in combi-
nation with vancomycin was tested. For this, 21 mM of MgCl2 and 1.0 mg/mL of
LPS purified from E.coli O55:B5 (Sigma-Aldrich) were added to the CAMHB
medium during the MIC and synergistic tests. The condition for the tests and the
analysis of the plates were performed as described above for the MIC tests.
Outer-membrane permeability test. The integrity of the outer-membranes was
analyzed measuring the 1-N-phenylnaphthylamine (NPN) uptake after the treat-
ment with the peptide. The outer-membrane acts as a permeability barrier that
excludes hydrophobic compounds as NPN. If the outer-membrane is altered, the
dye can enter reaching the phospholipid layer which results in a prominent
fluorescence60. Briefly, the peptides and/or antibiotics were placed in a 96-well
plate at 2× the desired final concentration in HEPES buffer plus glucose (GHEPES)
(5 mM HEPES, 5 mM glucose). Meantime, the Gram-negative bacteria were grown
in LB until an OD600 of 1. After that, they were washed twice in GHEPES buffer
and 2-fold diluted in the same buffer. NPN was dissolved in acetone and added to
the cells at 30 µM final concentration, and after that, the bacteria were distributed
in the 96 wells plates previously prepared with the antimicrobials at a final OD600
of ~0.25. Immediately the fluorescence for the dye was measured at an excitation/
emission range of 350/420 nm every 10 min during 1 h. Polymyxin B was used as a
positive control and non-treated cells as negative. All the tests were performed in
triplicate.
Hemolytic activity and cytotoxicity. Cytotoxicity and the hemolytic activity of
peptide D-11 alone as well as in combination with vancomycin were tested by the
company Fidelta Ltd (Zagreb, Croatia) and by Wuhan Elabscience Biotechnology
Co., Ltd (Wuhan, China). Hemolytic activity was determined with fresh human red
blood cells (hRBCs)28. The hRBCs were centrifuged (1000×g, 5 min) and the
supernatant was discarded. The pellets were washed three times with PBS and
diluted in PBS to make the cell stock solution with a cell density of 2*108 cells/mL.
The hRBCs suspensions were incubated with vancomycin, the peptide D-11 and
their combinations at various concentrations, as indicated. 1% Triton X-100 and
PBS were used as controls. The cells were incubated at 37 °C for 1 h and centrifuged
at 2000 rpm for 5 min. The supernatant was transferred to a new 96-well plate and
hemolysis was monitored by measuring the absorbance at 450 nm (OD450).
Hemolysis levels were calculated as percentage. % hemolysis= 100 × (As−A0)/
(At−A0), where As, A0, and At are the absorbance of the hRBCs suspension in PBS
with antimicrobial agents (As), without antimicrobial agents (A0), and with 1%
Triton X-100 (At). Based on these data, other parameters, such as the HC50
(concentration that causes 50% hemolysis of hRBCs), the MHC (minimal hemo-
lytic concentration that caused 10% hemolysis of hRBCs), and the TI (therapeutic
index) were calculated. For the TI calculation (TI=MHC/GM), other factors as
the GM (geometric mean of MIC value of all the Gram-negative strains tested)
were calculated.
A human embryonic kidney cell line HEK-293 was used to assess the cell
viability61. 96-well plates were seeded with HEK-293 cells at a concentration of
3*105 cells/well in 100 µL of DMEM growth medium supplemented with 1%
NEAA and 10% FBS. Border wells were filled with 100 µL of sterile PBS.
Vancomycin and peptide D-11 were added to the cells the next day at various
concentrations. ATP levels were measured by adding 50 µL of CellTiter-Glo
reagent (Promega, Madison, US) to each well, and luminescence was measured
with a SpectraMax i3 microplate reader after 5 minutes of incubation. The potential
effect of the tested compounds on cell viability was determined by comparing the
signal obtained in the presence of different concentrations of the compounds with
those obtained in the control wells. All these tests were performed in triplicate.
Antimicrobial activity in blood. Briefly, blood from healthy donors was obtained
from Sanquin (certified Dutch organization responsible for meeting the need in
healthcare for blood and blood products, https://www.sanquin.nl/) and infected
with 108 CFU/mL of K. pneumoniae LMG 20218. After that, the infected blood was
split in two, and one of the tubes was inoculated with 4 µM of the peptide D-11,
and the blood was distributed at 0.5 mL in 2 mL Eppendorf tubes. Vancomycin was
added at 16, 8, 4, and 2 µM in the tubes that were incubated at 37 °C for 6 h with
gentle shaking. At 1, 2, 4, and 6 h 100 µL samples were taken from each one of the
tubes and decimal serially diluted in PBS. Drops of 10 µL of each one of the
dilutions were spotted on LB agar medium to follow the development of the
infection. The experiment was performed in triplicate. Non-infected blood, infected
blood, and blood plus peptide were used as a control.
In vivo antimicrobial activity test. As a proof of concept, an in vivo test for the
efficacy of the synergy was performed. An overnight P. aeruginosa PA14 culture
was inoculated into fresh LB medium (100-fold dilution) and grown until an OD600
of 1.0. The culture was washed twice and resuspended in 0.9% NaCl to 108 CFU/
mL. Four groups of five 6-week-old female BALB/c mice were used. They were
anesthetized with 7.5% chloral hydrate by intraperitoneal injection, and then
subcutaneously injected with 50 µL of the bacterial suspension at the dorsum of the
mice, giving a total infection bacterial number of ~5*106 CFU per mouse. One
hour post-infection, 50 µL of 0.9% NaCl (control group), vancomycin (3 mg/kg),
the peptide D-11 (10 mg/kg) and a combination of vancomycin and D-11 at the
previous concentrations, respectively, were injected into the infection area. After
24 h, the mice were sacrificed and the abscesses were excised to count the CFU. The
bacterial loads were determined by serial dilution and plating. All animal experi-
ments complied with the US and Chinese national guidelines for the use of animals
in research. The protocol was approved by the Animal Care and Use Committee of
the College of Life Sciences, Nankai University (permission number NK-04-2012).
All procedures involving animals were performed after animals were anesthetized.
The experimental results were analyzed with the GraphPad Prism software.
Statistic and reproducibility. All experiments were performed in replicates as
indicated.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author on request. Raw data used for Figs. 2 and 3 are shown in Supplementary Data 1.
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